` 601089 (Beijing Winsunny Pharmaceutical Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

B
601089
vs
S
Shanghai Composite

Over the past 12 months, Beijing Winsunny Pharmaceutical Co Ltd has significantly outperformed Shanghai Composite, delivering a return of +71% compared to the Shanghai Composite's +23% growth.

Stocks Performance
601089 vs Shanghai Composite

Loading
601089
Shanghai Composite
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
601089 vs Shanghai Composite

Loading
601089
Shanghai Composite
Difference
www.alphaspread.com

Performance By Year
601089 vs Shanghai Composite

Loading
601089
Shanghai Composite
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Beijing Winsunny Pharmaceutical Co Ltd vs Peers

Shanghai Composite
601089
JEF
JNJ
4312
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Beijing Winsunny Pharmaceutical Co Ltd
Glance View

Market Cap
5B CNY
Industry
Pharmaceuticals

In the bustling epicenter of China's pharmaceutical landscape lies Beijing Winsunny Pharmaceutical Co Ltd, a dynamic player that expertly navigates the intricacies of modern healthcare needs. Established as a frontrunner in the production of both active pharmaceutical ingredients (APIs) and finished dosage forms, Winsunny has carved out a niche by marrying traditional pharmaceutical craftsmanship with innovative technological advancements. The company focuses predominantly on the cardiovascular and gastrointestinal therapeutic segments, diligently working to bring cutting-edge treatments to global markets. Leveraging state-of-the-art research and development facilities, Winsunny fosters a culture of continuous innovation and stringent quality assurance, ensuring its offerings not only meet but often exceed regulatory requirements. This emphasis on quality and innovation anchors its reputation as a reliable partner in the pharmaceutical supply chain, both within China and internationally. Winsunny's financial health and traction in the market are built upon a versatile business model that capitalizes on both proprietary research and strategic partnerships. By investing heavily in R&D, the company pioneers new drugs while simultaneously improving existing formulations to enhance efficacy and safety profiles. Furthermore, Winsunny’s strategic alliances with global pharmaceutical giants enable it to expand its market reach and distribution networks. This synergistic approach, coupled with a keen eye on operational efficiencies, allows Winsunny to maintain competitive pricing without compromising on quality. As healthcare demands continue to evolve, the company stands agile, ready to adapt and address these shifts, ensuring its place as a stalwart in the pharmaceutical industry and a significant contributor to global health advancements.

Intrinsic Value
35.4 CNY
Undervaluation 26%
Intrinsic Value
Price
B
Back to Top